"This product will provide unique diagnostic information and have the potential to become a very valuable tool to help prevent cancer from spreading. High precision diagnostics of metastasis is a crucial part of successful cancer treatment. This technology can help physicians choose the best treatment earlier which can lead to better survival rates. I look forward to working with Cline to bring this to market as quickly as possible." - Theresa Vincent, PhD, Scientific Advisor, Uppsala University 

According to statistics, about 1 in 3 people risk developing cancer. Cline has initially chosen to focus development efforts on breast cancer, which is one of the three most prevalent forms of cancer worldwide. The World Health Organization estimates there are about 1.7 million new cases of breast cancer per year and that general forms of cancer will increase by 70% over the next 20 years. 

Within the world of cancer diagnostics, it's becoming more relevant, but also more complex, to interpret patient specific diagnostic data. More patient specific data will unlock the potential of tailored treatments and solve many of today's treatment issues where both under- and over treatment are problems related to both survival and quality of life. 

Cline strives to develop a product that is easy to read and use by the healthcare staff which provides confidence in difficult decisions. 

"The problem with today's advanced diagnostics is that a large number of parameters and a complex cross-talk between the inner and outer cell environments are considered to build a prognosis of what statistically might happen. Our idea is instead based on a very simple principle; measure what matters. Therefore, we measure the migratory behavior of the tumor cells from patients, instead of only relating to today's available tumor markers. " - Reza Mobini, Associate Professor, Gothenburg University

Based on the number of biopsies conducted each year in the US and Europe, the two largest markets globally, a competitively priced product could generate sales in excess of 150M USD annually with 10% market penetration based on the estimated number of breast cancer biopsies in 2023.  

"Cline's cancer diagnostic tool has the potential to be used across a variety of different forms of cancer. I see great potential for this technology to become an essential tool across the board for cancer diagnostics. By being able to treat the patient correctly, this not only dramatically improves patient care but lowers cost of treatment which is beneficial to both private and public healthcare." - Michael Andäng, PhD, Scientific Advisor, Uppsala University

According to a report from Grand View Research, the global market for new modern cancer diagnosis products is expected to be valued at no less than $ 33.7 billion in 2025. The potential and the great value of a more accurate and more individualized cancer diagnosis are increasingly drawn in parallel with growing business interest.

"As the cancer diagnostic project continues to progress, the reality of bringing this from the lab to the patient is very exciting. Now that Cline has begun to test their prototype on live tumor material, this is an important step taking us to being able to start the process of clinical trials." - Petra Szeszula, PhD, Scientific Advisor

More about Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase. Cline operates out of Gothenburg, Sweden and was founded in 2012 from a long-term research project in surface nanotechnology.

Cline Scientific AB  

Argongatan 2C
431 53  Mölndal

Telefon: 031-387 55 55 
E-post: info@clinescientific.com 
Hemsida: www.clinescientific.com